Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has initiated a Phase 2c clinical trial of PH-10 for psoriasis. This multicenter, randomized controlled Phase 2c study is expected to enroll up to 90 subjects at four different sites, beginning in late December.
More...
Linear Mode
